Scarica l'app Stockscreener
781.67
1.41%
10.88
Dopo l'orario di chiusura:
781.67
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$770.79
Aprire:
$760.91
Volume 24 ore:
726.22K
Relative Volume:
0.84
Capitalizzazione di mercato:
$82.64B
Reddito:
$14.34B
Utile/perdita netta:
$4.50B
Rapporto P/E:
18.81
EPS:
41.5626
Flusso di cassa netto:
$3.77B
1 W Prestazione:
+0.26%
1M Prestazione:
+1.35%
6M Prestazione:
+33.17%
1 anno Prestazione:
+11.23%
Intervallo 1D:
$760.91
$786.68
Intervallo di 1 settimana:
$753.79
$792.67
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Sanofi (SNY) and Regeneron (REGN) Gain EMA Nod for Dupixent Expa - GuruFocus
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline - TradingView
Sarcopenia Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Oncocross, Biophytis, MyMD Pharmaceuticals, Novartis, Regeneron Pharma, Merck - StreetInsider
Why Dupixent Keeps Regeneron A Top Big Pharma Pick - Seeking Alpha
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment - The Manila Times
Mitsubishi UFJ Asset Management Co. Ltd. Has $121.55 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Erste Asset Management GmbH Sells 4,661 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Banco Santander S.A. - MarketBeat
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Dupixent’s New FDA Approval For Allergic Fungal Rhinosinusitis - simplywall.st
Regeneron Renews Sponsorship of the Regeneron Science Talent Sear - The National Law Review
K.J. Harrison & Partners Inc Has $2.46 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Dana Investment Advisors Inc. Buys Shares of 5,313 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children - Pharmaceutical Executive
Global Ophthalmic Drugs Market Estimated at US$41.88 Billion in 2026; Projected to Grow at 7.9% CAGR Through 2036 - GlobeNewswire Inc.
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by TD Asset Management Inc - MarketBeat
FDA approves Dupixent as first treatment for AFRS - The Pharma Letter
Fox Run Management L.L.C. Acquires Shares of 4,413 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years - The Globe and Mail
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Cooling - Yahoo Finance
Should FDA Approval of Dupixent in AFRS Patients Prompt Action From Regeneron Pharmaceuticals (REGN) Investors? - Yahoo Finance
Is Dupixent’s First AFRS Approval Altering The Investment Case For Regeneron Pharmaceuticals (REGN)? - simplywall.st
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis - WebWire
FDA Approves Regeneron's (REGN) Dupixent for Allergic Fungal Rhi - GuruFocus
Regeneron Pharmaceuticals, Sanofi Secure FDA Approval for Dupixent Sinus Treatment - marketscreener.com
Sanofi, Regeneron's Allergic Fungal Rhinosinusitis Treatment Gets US FDA Clearance - marketscreener.com
Sanofi and Regeneron's Dupixent approved in the U.S. for Allergic Fungal Rhinosinusitis - marketscreener.com
Regeneron Pharmaceuticals gains FDA approval for allergy treatment - Traders Union
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis - The Manila Times
Dupixent cuts sinus surgeries, steroids 92% in fungal allergy - Stock Titan
Is Regeneron Pharmaceuticals Inc Gaining or Losing Market Support? - Benzinga
M. Kulyk & Associates LLC Purchases 10,368 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Periodic Fever Market Analysis: Trends, Demand, Size, and Key - openPR.com
FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review - Finviz
Regeneron Pharmaceuticals (NASDAQ:REGN) Director Huda Zoghbi Sells 1,638 Shares - MarketBeat
Is Regeneron (REGN) Still Reasonably Priced After Its Multi Year Share Price Run? - simplywall.st
Regeneron Pharmaceuticals (REGN) Stock Analysis: Navigating Growth with a Promising 11.58% Upside - DirectorsTalk Interviews
Regeneron Pharmaceuticals, Inc. $REGN is Mcdonald Capital Investors Inc. CA's 5th Largest Position - MarketBeat
Lansforsakringar Fondforvaltning AB publ Has $21.55 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Citigroup Inc. Lowers Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How (REGN) Movements Inform Risk Allocation Models - Stock Traders Daily
Stevens Capital Management LP Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Ellerson Group Inc. ADV - MarketBeat
Regeneron: A Long-Term Investment in Biotech - Intellectia AI
Regeneron Stock: Here’s Why Four Expected FDA Approvals Could Push its 36% Rally Even Higher - TIKR.com
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $850, Maintains Outperform Rating - marketscreener.com
Regeneron Pharmaceuticals, Inc. $REGN is Persistent Asset Partners Ltd's 5th Largest Position - MarketBeat
Is Wall Street Bullish or Bearish on Regeneron Pharmaceuticals Stock? - Barchart.com
China Universal Asset Management Co. Ltd. Has $12.01 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Compass Wealth Management LLC Invests $2.04 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diabetic Macular Edema Market to Reach US$ 7.44 Billion by 2033 - openPR.com
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.60%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):